- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Molecular Biology International
Volume 2011 (2011), Article ID 938435, 4 pages
Establishment of Methylation-Specific PCR for the Mouse p53 Gene
1Department of Radiation Biology and Health, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka Yahatanishi-ku, Kitakyushu 807-8555, Japan
2Department of Immunology and Parasitology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka Yahatanishi-ku, Kitakyushu 807-8555, Japan
Received 30 March 2011; Revised 8 September 2011; Accepted 19 September 2011
Academic Editor: George A. Calin
Copyright © 2011 Ryuji Okazaki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- S. F. Gilbert, “Ageing and cancer as diseases of epigenesis,” Journal of Biosciences, vol. 34, no. 4, pp. 601–604, 2009.
- J. P. Issa, “CpG island methylator phenotype in cancer,” Nature Reviews Cancer, vol. 4, no. 12, pp. 988–993, 2004.
- P. Hainaut and M. Hollstein, “p53 and human cancer: the first ten thousand mutations,” Advances in Cancer Research, vol. 77, pp. 81–137, 2000.
- P. G. Corn, S. J. Kuerbitz, M. M. van Noesel et al., “Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with CpG island methylation,” Cancer Research, vol. 59, no. 14, pp. 3352–3356, 1999.
- J. G. Herman, J. R. Graff, S. Myohanen, B. D. Nelkin, and S. B. Baylin, “Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 18, pp. 9821–9826, 1996.
- M. C. Fruhwald, M. S. O'Dorisio, Z. Dai et al., “Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas—implications for tumor biology and potential clinical utility,” Oncogene, vol. 20, no. 36, pp. 5033–5042, 2001.
- V. J. Amatya, U. Naumann, M. Weller, and H. Ohgaki, “TP53 promoter methylation in human gliomas,” Acta Neuropathologica, vol. 110, no. 2, pp. 178–184, 2005.
- C. Zhang, X. Guo, G. Jiang et al., “CpG island methylator phenotype association with upregulated telomerase activity in hepatocellular carcinoma,” International Journal of Cancer, vol. 123, no. 5, pp. 998–1004, 2008.
- Y. Gondo, K. Nakamura, K. Nakao et al., “Gene replacement of the p53 gene with the lacZ gene in mouse embryonic stem cells and mice by using two steps of homologous recombination,” Biochemical and Biophysical Research Communications, vol. 202, no. 2, pp. 830–837, 1994.
- T. Norimura, S. Nomoto, M. Katsuki, Y. Gondo, and S. Kondo, “p53-dependent apoptosis suppresses radiation-induced teratogenesis,” Nature Medicine, vol. 2, no. 5, pp. 577–580, 1996.
- R. Okazaki, A. Ootsuyama, H. Kakihara et al., “Dynamics of delayed p53 mutations in mice given whole-body irradiation at 8 weeks,” International Journal of Radiation Oncology Biology Physics, vol. 79, no. 1, pp. 247–254, 2011.
- D. M. Shin, M. Kucia, and M. Z. Ratajczak, “Nuclear and chromatin reorganization during cell senescence and aging—a mini-review,” Gerontology, vol. 57, pp. 76–84, 2010.
- M. Esteller, “Relevance of DNA methylation in the management of cancer,” Lancet Oncology, vol. 4, no. 6, pp. 351–358, 2003.